BRAF and central nervous system cancer: In order to understand mechanisms of adaptive resistance to BRAFi/MEKi in glioma, we evaluated protein expression in a cohort of human BRAF V600E mutant glioma specimens obtained preceding treatment with BRAFi/MEKi and compared them against tissue obtained at the time of progression (Figure 1A).